Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.35 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | FPR1 | P21462 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPR3 | P17342 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | XBP1 | P17861 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13537087 | 0.91 | CYP17A1 (0.37) | NPSR1CTSSCTSKCYP17A1ATR | |
| SCHEMBL349940 | 0.83 | NPSR1 (0.40) | NPSR1CTSSCTSKCYP17A1ATR | |
| SCHEMBL12359024 | 0.80 | NPSR1 (0.41) | NPSR1CNR2FPR1MAPTLMNA | |
| SCHEMBL12306124 | 0.80 | NPSR1 (0.41) | NPSR1CNR2FPR1MAPTMEN1 | |
| SCHEMBL344041 | 0.80 | KCNQ4 (0.42) | NPSR1CNR2CTSSCTSKCYP17A1 | |
| SCHEMBL12306126 | 0.80 | NPSR1 (0.47) | NPSR1CNR2FPR1MAPTMEN1 | |
| SCHEMBL347028 | 0.79 | NPSR1 (0.46) | NPSR1CNR2FPR1MAPTLMNA | |
| SCHEMBL12359164 | 0.79 | NPSR1 (0.39) | NPSR1CNR2FPR1MAPTLMNA | |
| SCHEMBL12318935 | 0.77 | NPSR1 (0.37) | NPSR1CNR2GRM2MAPTLMNA | |
| SCHEMBL12359025 | 0.76 | NPSR1 (0.36) | NPSR1CNR2GRM2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321319-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20110223131-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| WO-2011106445-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
| US-7998950-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998950-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| WO-2010011959-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022508-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022508-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110223131-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NPSR1 4462/4885CNR2 4830/4885CTSS 925/4885 |
| US-20100022508-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NPSR1 4462/4885CNR2 4830/4885CTSS 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.